A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females

Journal of Thoracic Oncology

Volumn 9, Issue 11, 2014, Pages 1647-1655

  Kang, Hyo Gyoung ^a   Lee, Shin Yup ^b,c   Jeon, Hyo Sung ^a   Choi, Yi Young ^a   Kim, Soyoun ^a   Lee, Won Kee ^b   Lee, Hyun Chul ^d   Choi, Jin Eun ^a   Bae, Eun Young ^a   Yoo, Seung Soo ^b,c   Lee, Jaehee ^b   Cha, Seung Ick ^b   Kim, Chang Ho ^b   Lee, Myung Hoon ^d   Kim, Young Tae ^e,f   Kim, Jin Hee ^f   Hong, Yun Chul ^g   Kim, Yeul Hong ^h   Park, Jae Yong ^a,b,c  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d D and P Biotech   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f Seoul National University   (South Korea)

^g Seoul National University College of Medicine   (South Korea)

^h Korea University   (South Korea)

Author keywords

Lung cancer; Never smokers; Polymorphism

Indexed keywords

COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; PROTEIN P63; RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; COLONY STIMULATING FACTOR RECEPTOR;

A549 CELL LINE; ADULT; ARTICLE; CANCER GROWTH; CANCER SUSCEPTIBILITY; CODON; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HUMAN; INTRON; KOREAN (PEOPLE); LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REPLICATION STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; CASE CONTROL STUDY; DNA MICROARRAY; GENETIC PREDISPOSITION; GENETICS; HEK293 CELL LINE; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

EID: 84925750728     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000310     Document Type: Article

References (53)

1. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer 2007;7:778-790.
2. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:561-570.
3. Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006;24:2245-2251.
4. Ger LP, Liou SH, Shen CY, et al. Risk factors of lung cancer. J Formos Med Assoc 1992;91(suppl 3):S222-S231.
5. Scagliotti GV, Longo M, Novello S. Nonsmall cell lung cancer in never smokers. Curr Opin Oncol 2009;21:99-104.
6. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 2005;93:825-833.
7. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis 2007;28:507-518.
8. Raimondi S, Boffetta P, Anttila S, et al. Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. Mutat Res 2005;592:45-57.
9. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-622.
10. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-637.
11. McKay JD, Hung RJ, Gaborieau V, et al.; EPIC Study. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008;40:1404-1406.
12. Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008;40:1407-1409.
13. Wang Y, Broderick P, Matakidou A, Eisen T, Houlston RS. Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers. Carcinogenesis 2010;31:234-238.
14. Hsiung CA, Lan Q, Hong YC, et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet 2010;6:pii: e1001051.
15. Li Y, Sheu CC, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 2010;11:321-330.
16. Landi MT, Chatterjee N, Caporaso NE, et al. GPC rs2352028 variant and risk of lung cancer in never smokers. Lancet Oncol 2010;11:714-716.
17. Ahn MJ, Won HH, Lee J, et al. The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Hum Genet 2012;131:365-372.
18. Hosgood HD 3rd, Wang WC, Hong YC, et al. Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among neversmoking females in Asia. Hum Genet 2012;131:1197-1203.
19. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008;299:1335-1344.
20. Witte JS. Genome-wide association studies and beyond. Annu Rev Public Health 2010;31:9-20.
21. On beyond GWAS. Nat Genet 2010;42:551.
22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
23. Lee SY, Choi YY, Choi JE, et al. Polymorphisms in the caspase genes and the risk of lung cancer. J Thorac Oncol 2010;5:1152-1158.
24. Bae EY, Lee SY, Kang BK, et al. Replication of results of genome-wide association studies on lung cancer susceptibility loci in a Korean population. Respirology 2012;17:699-706.
25. Laskowski RA, MacArthur MW, Moss DS, et al. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-291.
26. Eswar N, Webb B, Marti-Renom MA, et al. Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics 2006;Supplement 15:5.6.1-5.6.30.
27. Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000;29:291-325.
28. Reilly JT. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol 2002;116:744-757.
29. Morandi A, Barbetti V, Riverso M, Dello Sbarba P, Rovida E. The colonystimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. PLoS One 2011;6:e27450.
30. Himes SR, Sester DP, Ravasi T, Cronau SL, Sasmono T, Hume DA. The JNK are important for development and survival of macrophages. J Immunol 2006;176:2219-2228.
31. Stanley ER, Guilbert LT, Tushinski RJ, et al. CSF-1 A mononuclear phagocyte lineage-specific hemopoietic growth factor. J Cell Biochem 1983;21:151-159.
32. Slamon DJ, deKernion JB, Verma IM, Cline MJ. Expression of cellular oncogenes in human malignancies. Science 1984;224:256-262.
33. Horiguchi J, Sherman ML, Sampson-Johannes A, Weber BL, Kufe DW. CSF-1 and C-FMS gene expression in human carcinoma cell lines. Biochem Biophys Res Commun 1988;157:395-401.
34. Kacinski BM. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev 1997;46:71-74.
35. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-740.
36. Smith HO, Anderson PS, Kuo DY, et al. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin Cancer Res 1995;1:313-325.
37. Chambers SK, Wang Y, Gertz RE, Kacinski BM. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 1995;55:1578-1585.
38. Sapi E, Flick MB, Rodov S, et al. Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res 1996;56:5704-5712.
39. Rohrschneider LR, Rothwell VM, Nicola NA. Transformation of murine fibroblasts by a retrovirus encoding the murine c-fms proto-oncogene. Oncogene 1989;4:1015-1022.
40. Graziano V, De Laurenzi V. Role of p63 in cancer development. Biochim Biophys Acta 2011;1816:57-66.
41. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011;18:1487-1499.
42. Miki D, Kubo M, Takahashi A, et al. Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet 2010;42:893-896.
43. Wang Y, Broderick P, Matakidou A, Vijayakrishnan J, Eisen T, Houlston RS. Variation in TP63 is associated with lung adenocarcinoma in the UK population. Cancer Epidemiol Biomarkers Prev 2011;20:1453-1462.
44. Hu QY, Jin TB, Wang L, et al. Genetic variation in the TP63 gene is associated with lung cancer risk in the Han population. Tumour Biol 2014;35:1863-1866.
45. Hsieh JJ, Zhou S, Chen L, Young DB, Hayward SD. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A 1999;96:23-28.
46. Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, Hayward SD. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol 1996;16:952-959.
47. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004;4:850-860.
48. Chanock SJ, Manolio T, Boehnke M, et al. Replicating genotype-phenotype associations. Nature 2007;447:655-660.
49. Sjödin A, Guo D, Sørhaug S, Bjermer L, Henriksson R, Hedman H. Dysregulated secretoglobin expression in human lung cancers. Lung Cancer 2003;41:49-56.
50. Tan M, Song X, Zhang G, et al. Overexpression of adenylate cyclaseassociated protein 1 is associated with metastasis of lung cancer. Oncol Rep 2013;30:1639-1644.
51. Park HJ, Kim BG, Lee SJ, et al. Proteomic profiling of endothelial cells in human lung cancer. J Proteome Res 2008;7:1138-1150.
52. Kumar MS, Armenteros-Monterroso E, East P, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature 2014;505:212-217.
53. Marchetti A, Felicioni L, Pelosi G, et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat 2008;29:609-616.